GERN Geron

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.

Company profile

John Scarlett
Fiscal year end
Former names
IRS number

GERN stock data



10 May 21
31 Jul 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Geron earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 31.54M 31.54M 31.54M 31.54M 31.54M 31.54M
Cash burn (monthly) (positive/no burn) (positive/no burn) 9.48M 7.37M 10.91M 6.1M
Cash used (since last report) n/a n/a 38.1M 29.63M 43.83M 24.5M
Cash remaining n/a n/a -6.57M 1.91M -12.3M 7.03M
Runway (months of cash) n/a n/a -0.7 0.3 -1.1 1.2

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
30 Jun 21 Spiegel Robert J. Common Stock Grant Aquire A No No 0 5,097 0 124,594
11 May 21 Lawlis V Bryan Stock Option Common Stock Grant Aquire A No No 1.39 83,000 115.37K 83,000
11 May 21 Molineaux Susan Stock Option Common Stock Grant Aquire A No No 1.39 83,000 115.37K 83,000
11 May 21 Spiegel Robert J. Stock Option Common Stock Grant Aquire A No No 1.39 83,000 115.37K 83,000
11 May 21 Eastham Karin Stock Option Common Stock Grant Aquire A No No 1.39 83,000 115.37K 83,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

45.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 147 152 -3.3%
Opened positions 19 16 +18.8%
Closed positions 24 16 +50.0%
Increased positions 50 54 -7.4%
Reduced positions 39 36 +8.3%
13F shares
Current Prev Q Change
Total value 423.87M 337.74M +25.5%
Total shares 143.73M 175.4M -18.1%
Total puts 422.1K 486.3K -13.2%
Total calls 1.3M 899.5K +44.0%
Total put/call ratio 0.3 0.5 -39.7%
Largest owners
Shares Value Change
Ra Capital Management 30.13M $47.6M 0.0%
BLK Blackrock 26.48M $41.84M +5.8%
STT State Street 16.62M $26.27M +22.6%
Vanguard 16.43M $25.95M +1.5%
NEA Management 13.46M $21.27M 0.0%
Geode Capital Management 4.86M $7.68M +6.6%
FMR 4.11M $6.49M -0.0%
NTRS Northern Trust 3.02M $4.77M -6.2%
Great Point Partners 2.61M $4.12M -48.4%
Two Sigma Advisers 2.45M $3.87M +20.3%
Largest transactions
Shares Bought/sold Change
EcoR1 Capital 0 -18.94M EXIT
Perceptive Advisors 0 -13.46M EXIT
STT State Street 16.62M +3.07M +22.6%
Great Point Partners 2.61M -2.45M -48.4%
Burrage Capital Management 1.91M +1.91M NEW
Millennium Management 1.23M -1.89M -60.5%
BLK Blackrock 26.48M +1.46M +5.8%
Samsara BioCapital 0 -1.22M EXIT
Renaissance Technologies 0 -982.5K EXIT
D. E. Shaw & Co. 106.48K -916.08K -89.6%

Financial report summary

Management Discussion
  • Our results of operations have fluctuated from period to period and may continue to fluctuate in the future. Results of operations for any period may be unrelated to results of operations for any other period. Thus, historical results should not be viewed as indicative of future operating results.
  • We are subject to risks common to companies in our industry and at our stage of development, including, but not limited to, risks inherent in research and development efforts, including the development, manufacture, regulatory approval for and commercialization of, imetelstat; uncertainty of non-clinical and clinical trial results or regulatory approvals or clearances; the future development of imetelstat by us, including any future efficacy or safety results that may cause the benefit-risk profile of imetelstat to become unacceptable; overcoming disruptions and/or delays due to the COVID-19 pandemic; our need for future capital; enforcement of our patent and proprietary rights; reliance upon our consultants, licensees, investigators and other third parties; and potential competition. In order for imetelstat to be commercialized, we must conduct non-clinical tests and clinical trials to demonstrate the safety and efficacy of imetelstat, obtain regulatory approvals or clearances and enter into manufacturing, distribution and marketing arrangements, as well as obtain market acceptance. We do not expect to receive revenue based on sales of imetelstat for many years, if at all.
Content analysis
H.S. junior Avg
New words: abbreviated, accidental, accrual, Actuate, addressing, adequacy, aforementioned, answer, apparent, Ascentage, behalf, Biden, Book, broad, callable, cardiac, competitor, confirming, CPRA, CR, deal, debarred, deceptive, denial, denied, deny, deter, disadvantage, disagreement, disqualified, dual, educate, EEA, employ, endeavor, entirety, exemplify, expert, fluidity, formulary, fraudulent, Galecto, GCP, GMP, gradual, gradually, hearing, hybrid, illegal, Importantly, improper, inconsistent, inventor, IWG, leader, legislature, liable, MAA, marginal, Middle, misconduct, misrepresentation, misrepresentative, modernizing, Nonrefundable, notwithstanding, Orange, outsource, pace, paragraph, pelabresib, penalized, percentage, persuade, post, posted, PR, preclinical, prematurely, preparatory, question, reassessed, repolarization, safeguard, satisfaction, shut, slower, speculative, Speed, split, substitute, Subtopic, Supreme, Switching, train, training, tyrosine, understand, unfair, unlawful, unmanaged, unnecessarily, unreliable, usage, vaccinated, vaccine, version, vision, voluntary, Warp, workforce
Removed: abnormality, al, amendment, appointed, arbitration, assessing, Australian, bill, called, carryback, certification, chromosomal, classification, closed, Commonwealth, conserve, cooperation, correlating, counsel, counterparty, County, cyber, DBA, Dear, deduction, deletion, directed, discontinue, discover, discretionary, diverse, diversify, dollar, dysfunctional, earliest, enactment, enrichment, essential, examined, FBR, fight, Germany, Governor, growing, Hereditary, hire, hiring, identifiable, inappropriate, Interaction, interpret, invalidity, jeopardize, leased, Litig, malignant, Mateo, Menlo, merit, metabolite, minimal, moderately, moving, national, Nonemployee, offer, originating, Park, patentee, personally, plaintiff, poor, practicable, prejudice, presence, presenting, President, proceed, progenitor, proliferation, Promega, promptly, promulgation, publicly, reevaluating, refuse, regained, regional, reimbursed, remeasure, rescinded, reveal, San, shift, situation, spending, suit, temporarily, tested, transmitting, Trump, unanticipated, unavoidable, uncontrolled, underwritten, undetermined, unjust, Urgent, weakened, widespread, withholding, word